（编辑 任世碧） 证券日报网讯 1月15日，奇德新材发布2025年年度业绩预告称，公司预计2025年归属于上市公司股东的 净利润为1800万元至2080万元，比上年同期增长107.21%至139.44%。 ...

Company Overview - Guoen Co., Ltd. (002768) is undergoing a listing hearing on the Hong Kong Stock Exchange, sponsored exclusively by China Merchants Securities International. The company operates in two main segments: Advanced Chemicals (Chemical New Materials) and Health Products (Gelatin, Collagen, and related upstream and downstream products) [1] Advanced Chemicals Segment - The Advanced Chemicals segment focuses on the chemical new materials industry, offering products such as green petrochemical materials (e.g., aromatic olefins, styrene, polystyrene) and organic polymer modified materials and composites. These products serve downstream industries including automotive, new energy, and home appliances [1] - According to Frost & Sullivan, Guoen Co., Ltd. is the second largest company in China for organic polymer modified materials and organic polymer composites by sales revenue in 2024, holding a market share of 2.5%. It is also the largest producer of polystyrene in China by production capacity in 2024 [1] Health Products Segment - The Health Products segment focuses on the natural collagen industry, developing collagen peptide derivatives and end products through its subsidiary Dongbao Biological (300239). The primary customers are medical and pharmaceutical manufacturers [1] - Based on Frost & Sullivan's data, Guoen Co., Ltd. ranks as the second largest producer of bone gelatin in China by production volume in 2024, and it is the largest domestic brand in this category. Additionally, it is the second largest domestic brand in the hollow capsule production sector in China, according to 2024 production volume estimates [1] Market Outlook - The market for organic polymer modified materials and organic polymer composites in China is projected to grow from RMB 544.8 billion in 2024 to RMB 1,037.5 billion by 2029, reflecting a compound annual growth rate (CAGR) of 14.1% [2]

Group 1 - The core viewpoint of the article is that Qingdao Guoen Technology Co., Ltd. has passed the listing hearing on the Hong Kong Stock Exchange, with China Merchants Securities International as the sole sponsor, focusing on new chemical materials and gelatin, collagen products [1] Group 2 - Guoen Technology serves the chemical and health industries, engaging in the R&D, production, and sales of products for industrial and commercial use [3] - The company has a diverse client base, including manufacturers in downstream industries such as automotive, new energy, and home appliances, as well as medical and pharmaceutical manufacturers in the health sector [3] - Guoen Technology is the second-largest company in China for organic polymer modified materials and organic polymer composite materials by sales revenue, holding a market share of 2.5% in 2024 [3] - The company is also the largest producer of polystyrene in China by production capacity in 2024 [3] Group 3 - Guoen Technology focuses on the natural collagen industry, with its subsidiary Dongbao Biological leveraging a vertical integration strategy to cover the entire value chain from collagen to end products [4] - The company is the second-largest producer of bone gelatin in China by production volume and the second-largest domestic brand in the hollow capsule industry by production volume in 2024 [5] Group 4 - The market size for organic polymer modified materials and organic polymer composite materials is projected to grow from RMB 303.8 billion in 2020 to RMB 544.8 billion in 2024, with a compound annual growth rate (CAGR) of 15.7% [5] - Guoen Technology's revenues for the fiscal years 2022, 2023, 2024, and the first ten months of 2025 are approximately RMB 13.41 billion, RMB 17.44 billion, RMB 19.19 billion, and RMB 17.44 billion respectively [5][6] - The company's net profits for the same periods are approximately RMB 724 million, RMB 540 million, RMB 721 million, and RMB 721 million [5][6]

Core Viewpoint - Qingdao Guoen Technology Co., Ltd. is preparing for its listing on the Hong Kong Stock Exchange, focusing on new chemical materials and gelatin, with a strong emphasis on both the chemical and health industries [1]. Group 1: Company Overview - Guoen Technology specializes in the research, production, and sales of products for the chemical and health industries, serving clients in sectors such as automotive, renewable energy, and healthcare [3]. - The company is recognized as the second-largest producer of organic polymer modified materials and organic polymer composite materials in China, holding a market share of 2.5% as of 2024 [4]. Group 2: Product and Market Position - In the chemical sector, Guoen's product range includes upstream green petrochemical materials and midstream organic polymer modified materials, catering to diverse applications in electronics, automotive, and energy storage [4]. - In the health sector, the company focuses on the natural collagen industry, with its subsidiary Dongbao Bio leveraging a vertically integrated strategy to cover the entire value chain from collagen to end products [5]. Group 3: Financial Performance - The company's revenue for the fiscal years 2022, 2023, 2024, and the first ten months of 2025 were approximately RMB 134.06 billion, RMB 174.39 billion, RMB 191.88 billion, and RMB 174.44 billion, respectively [6]. - The net profit for the same periods was RMB 7.24 billion, RMB 5.4 billion, RMB 7.21 billion, and RMB 7.21 billion [6].

Group 1: Company Overview - Qingdao Guoen Technology Co., Ltd. (002768.SZ) is focused on new chemical materials and gelatin, collagen upstream and downstream products, and has passed the listing hearing on the Hong Kong Stock Exchange [1] - The company serves the chemical and health industries, primarily engaged in the R&D, production, and sales of products for industrial and commercial use [3] Group 2: Industry Position - In the chemical industry, Guoen Technology is the second-largest company in China for organic polymer modified materials and organic polymer composite materials, with a market share of 2.5% as of 2024 [4] - The company is also the largest producer of polystyrene in China by production capacity as of 2024 [4] Group 3: Product and Market Focus - Guoen Technology focuses on the natural collagen industry, with a vertical integration strategy that covers collagen peptide derivatives to end products [5] - The company is the second-largest producer of bone gelatin in China and the second-largest domestic brand in the hollow capsule production industry as of 2024 [6] Group 4: Market Growth - The market size for organic polymer modified materials and organic polymer composite materials is projected to grow from RMB 303.8 billion in 2020 to RMB 544.8 billion in 2024, with a compound annual growth rate (CAGR) of 15.7% [6] - The market is expected to continue growing at a CAGR of 14.1% from 2025 to 2029, reaching RMB 1,037.5 billion by 2029 [6] Group 5: Financial Performance - Guoen Technology's revenues for the fiscal years 2022, 2023, 2024, and the first ten months of 2025 were approximately RMB 13.41 billion, RMB 17.44 billion, RMB 19.19 billion, and RMB 17.44 billion respectively [6][7] - The company reported net profits of RMB 724 million, RMB 540 million, RMB 721 million, and RMB 721 million for the same periods [6][8]

Core Viewpoint - Weifang Yaxing Chemical Co., Ltd. has announced the termination of its acquisition of 100% equity in Shandong Tianyi Chemical Co., Ltd., marking another setback in its attempts to transform through external mergers and acquisitions since facing operational difficulties in 2019 [1][2]. Group 1: Acquisition Termination - The termination of the acquisition is attributed to the failure of the parties involved to reach consensus on key issues such as core demands and asset valuation [1][2]. - The acquisition was initially seen as a crucial step for Yaxing Chemical to enhance its profitability and core competitiveness, as Tianyi Chemical is a leading player in the brominated flame retardant sector with a high market share [2][3]. Group 2: Internal Projects and Future Strategy - Following the termination, Yaxing Chemical's focus has shifted entirely to internal projects, with recent announcements of trial production for its high-end materials project and other chemical projects [3]. - These internal projects are viewed as critical for the company's transformation and profitability, although they face uncertainties in market development and cost control [3][4]. Group 3: Historical Context and Industry Challenges - This is not the first time Yaxing Chemical has faced challenges in its transformation efforts, as previous attempts at mergers and acquisitions have also failed, reflecting broader challenges in the chemical industry regarding valuation expectations and market realities [4][5]. - Experts suggest that other chemical companies under transformation pressure should optimize their acquisition strategies by thoroughly assessing technical feasibility and market risks during due diligence [5].

Group 1 - The core viewpoint is that the expansion of AI infrastructure will drive the chemical new materials sector into a period of prosperity, with capital expenditures (Capex) on the rise and data centers entering a phase of concentrated construction and delivery [1] - Key upstream materials such as electronic resins, Q fabrics, and precursors will benefit from the dual drivers of new capacity construction and hardware iteration upgrades [1] - AI applications are accelerating penetration across the entire chemical supply chain, focusing on high-risk inspections with "AI + robotics" in equipment, molecular discovery and process optimization with "AI + automation" in R&D, and AI-assisted formula upgrades and new material iterations in products [1] Group 2 - The current commercialization path of AI is clear, transitioning from a "technology validation phase" to a "scale operation phase," enhancing the certainty of new material demand as the link between revenue and computing power investment gradually closes [1] - The New Materials 50 ETF (159761) tracks the New Materials Index (H30597), which focuses on the new materials industry by selecting listed companies involved in advanced basic materials, key strategic materials, and cutting-edge new materials [1] - The index components cover high-performance composite materials and new functional materials, characterized by high growth and innovation, with a focus on the chemical and non-metallic new materials sectors [1]

倘於適當時候向香港公眾人士提出要約或邀請，有意投資者務請僅依據送呈香港公司註冊處處長登記的本 公司招股章程作出投資決定，招股章程的文本將於發售期內向公眾提供。 (a) 本文件僅為向香港公眾人士提供有關本公司的資料，概無任何其他目的。投資者不應根據本文件中 的資料作出任何投資決定； (b) 在聯交所網站登載本文件或補充、修訂或更換附頁，並不引起本公司、其獨家保薦人、整體協調 人、顧問及包銷團成員須在香港或任何其他司法管轄區進行發售活動的任何責任。本公司最終會否 進行發售仍屬未知之數； (c) 本文件或補充、修訂或更換附頁的內容未必會在實際最終的上市文件內全部或部分轉載； (d) 本聆訊後資料集並非最終的上市文件，本公司可能不時根據聯交所證券上市規則作出更新或修訂； (e) 本文件並不構成向任何司法管轄區的公眾人士提呈出售任何證券的招股章程、發售通函、通知、通 告、小冊子或廣告，亦非邀請公眾人士提出認購或購買任何證券的要約，且不旨在邀請公眾人士提 出認購或購買任何證券的要約； (f) 本文件不得被視為誘使認購或購買任何證券，亦無意構成該等勸誘； (g) 本公司或其任何聯屬公司、保薦人、整體協調人、顧問或包銷團成員 ...

Group 1 - The core viewpoint of the article highlights the recent IPO activities in the Shanghai Stock Exchange, Shenzhen Stock Exchange, and Hong Kong Stock Exchange, with a focus on the performance of newly listed companies and their market valuations [2][8][12] - In the Shanghai Stock Exchange, only one company, Shaanxi Tourism, was listed during the period, with its stock price increasing by 72.18% from the issue price, reaching a market capitalization of approximately 10.7 billion yuan [3][2] - The Hong Kong Stock Exchange saw a more active IPO environment with seven companies listed, including notable performers like Zhipu Huazhang and MiniMax, which saw significant stock price increases of 79.35% and 141.21% respectively [9][10][11] Group 2 - Zhipu Huazhang, an AI company, achieved a market capitalization of approximately 91.7 billion HKD after a 79.35% increase in stock price [9] - MiniMax, another AI-focused company, experienced a remarkable 141.21% increase in stock price, leading to a market capitalization of around 123.1 billion HKD [10] - Other companies like Tian Shu Zhi Xin and Jing Feng Medical also reported substantial stock price increases, indicating a strong interest in tech and healthcare sectors [10][11] Group 3 - Several companies submitted IPO applications during the period, including Zhejiang Borui Biopharmaceutical and Hangzhou Deshi Biotechnology, indicating ongoing interest in the biotech sector [16][26] - The financial data of these companies show varying revenue and profit trends, with Borui Biopharmaceutical projecting revenues of 12.57 billion yuan and 16.23 billion yuan for 2023 and 2024 respectively [24][26] - Deshi Biotech reported revenues of 52.84 million yuan and 70.35 million yuan for the same periods, highlighting the growth potential in the medical imaging sector despite initial losses [27] Group 4 - Companies like Xizi Health and Sanisen Di are focusing on expanding their market presence in the health and nutrition sectors, with Xizi Health projecting revenues of 14.47 billion yuan and 16.92 billion yuan for 2023 and 2024 [36][38] - Sanisen Di aims to enhance its product competitiveness and expand its sales network, reflecting a trend towards innovation in the toy industry [39] - The financial performance of these companies indicates a mix of growth and challenges, with Xizi Health showing a profit increase while Sanisen Di is still working towards profitability [40][38] Group 5 - The article also discusses the performance of established companies like Laoxiangji, which is the largest Chinese fast-food brand, reporting revenues of 45.28 billion yuan in 2022 and projected growth in subsequent years [44] - Laoxiangji's market strategy includes optimizing its supply chain and expanding its store network, which is crucial for maintaining its competitive edge in the fast-food industry [43] - The financial outlook for Laoxiangji shows a steady increase in revenue and profit, indicating a strong market position despite potential risks associated with brand recognition and operational challenges [45][44]

Group 1 - The core message emphasizes the importance of the 20th Central Committee's Fourth Plenary Session in guiding the company's strategic planning for the 14th and 15th Five-Year Plans, particularly in achieving significant progress towards socialist modernization [1] - The company aims to focus on its core business and develop a competitive and innovative green low-carbon chemical new materials industry cluster [2] - There is a commitment to enhance the company's risk resistance capabilities through measures that strengthen the supply chain and improve technological and talent support for high-quality development [2] Group 2 - The company plans to actively develop productive service industries to drive overall industrial growth [2] - There is an intention to explore the best pathways for modern agricultural comprehensive service providers, transforming the integrated circular economy model into new opportunities for business development [2] - The company will conduct in-depth research on the industrial layout in the southern Xinjiang region to contribute significantly to local economic and social development [2]